| Literature DB >> 35078779 |
Julia Romberg1, Marko Wilke2, Christoph Allgaier3, Thomas Nägele4, Corinna Engel3, Christian F Poets5, Axel Franz5.
Abstract
BACKGROUND: MRI allows a detailed assessment of brain structures in preterm infants, outperforming cranial ultrasound. Neonatal MR-based brain volumes of preterm infants could serve as objective, quantitative and reproducible surrogate parameters of early brain development. To date, there are no reference values for preterm infants' brain volumes at term-equivalent age.Entities:
Keywords: infant development; magnetic resonance imaging; neonatology; neurology
Mesh:
Year: 2022 PMID: 35078779 PMCID: PMC9411894 DOI: 10.1136/archdischild-2021-322846
Source DB: PubMed Journal: Arch Dis Child Fetal Neonatal Ed ISSN: 1359-2998 Impact factor: 6.643
Figure 1Flow diagram for systematic review of retrieved studies. PMA, postmenstrual age.
Demographic variables of study populations
| Reference | N | Inclusion criteria | Site of recruitment | Study period | Birth weight (g) | Gestational age (weeks) Mean (SD) | SDS(Birthweight) (Mean(SD))/ % IUGR* | % Antenatal Corticosteroids (any) | % Postnatal Corticosteroids | % BPD | % PDA | % any IVH | PMA at scan (weeks) | MR scanner | Segmentation method |
| Blok | 36 | GA <32 weeks | Utrecht (NL) | 2007–2009 | 1027 (47) | 27.2 (1.7) | N/A | N/A | N/A | 42% | 28% | °I–IV: 38.9% | 41.4 (0.8) | 1.5 T Philips Intera | Semiautomatic |
| Ekblad | 209 | bw<1500 g and GA <32 weeks | Turku (FI) | 2001–2006 | 1121 (319)† | 29.0 (2.7) | −1.43 (1.61)/38% (SGA)† | N/A | 14%† | 14%† | 12.5% (missing information for 4) | °I–IV: 23.7% | ‡,† | 0.23 T Outlook GP Philips (n=126)/1.5 T Philips Gyroscan Intera (n=106) | Manual |
| Hansen-Pupp | 51 | GA <31 weeks | Lund (SE) | 2005–2007 | 888 (288) | 26.4 (1.9) | 24% | N/A | 26% hydrocortisone | N/A | N/A | § | 40.1 (0.6) | 3 T Siemens Magnetom Allegra | Manual |
| Hansen-Pupp | 49 | GA <31 weeks | Lund (SE) | 2005–2007 | 889 (290) | 26.0 (1.9) | −1.0 (1.2) | N/A | 24% hydrocortisone | N/A | N/A | N/A | 40.1 (0.6) | 3 T Siemens Magnetom Allegra | Manual |
| Inder | 119 (of 129)** | bw<1500 g and GA ≤32 weeks | n=100: Christchurch (NZ), n=29: Melbourne (AU) | 1998–2000 | 1040 (272) | 27.7 (2.2) | 22% | 87% | 2% | 21% | 32% | °I–IV: 17% | 40.2 (0.3) | 1.5 T General Electric Signa System | Semiautomatic |
| Kamino | 44(of 60)†† | GA <32 weeks | n=33: San Francisco (USA), n=27: Vancouver (CA) | 2010–2011 | N/A | UCSF: 28.1 (1.8) | N/A | UCSF: 100% | N/A | N/A | UCSF: | °I–°II: UCSF: 12%, UBC: 19% | 37.7 (3) | 1.5 T General Electric Signa/Siemens Avanto | Automatic |
| Moeskops | 85 | GA <28 weeks | Utrecht (NL) | 2008–2013 | N/A | 26.6±1.0 | N/A | N/A | N/A | N/A | N/A | °I: 11.8%, °II: 15.3%, °III: 5.9% | 41.1 (0.5) | 3 T Philips Achieva | Automatic |
| Parikh | 122 | bw<1000 g | Houston (USA) | 2005–2007 | 771 (144) | 26.7 (1.9) | 25% (SGA) | 70% | 18% ‘postnatal steroids for BPD’ | 52% | 33% with PDA surgery | °I–IV: 18% | 38.5 (2.2) | 1.5 T Reliant Medical GE-LX | Semiautomatic |
| Steinhorn | 192 | bw<1250 g and/or GA <30 weeks | Melbourne (AU) | 2001–2003 | 956 (223) | 27.5 (1.9) | 9% | 89% | 9% | N/A | N/A | °III–IV: 4% | ‘Between 38 and 42 weeks’ | 1.5 T General Electric Signa System | Manual |
| Stiver | 105 | GA <32 weeks | Toronto (CA) | 2008–2010 | N/A | 28.8 (1.8) | N/A | 69% | 6% ‘postnatal steroid exposure’ | N/A | N/A | °I/II: 19% | 41.9 (2.0) | 1.5 T Signa Twin EXCITE3 | Semiautomatic |
| Tam | 68 (of 172)¶ | GA<33 weeks | San Francisco (USA) | 2006–2009 | N/A | 27.5 (2.1) | N/A | 90% | 22% | 51% | 50% | °I–IV: 32,4% | 39.5 (1.3) | 1.5 T General Electric Signa/Siemens Avanto | Semiautomatic |
| Thompson | 202 | bw<1250 g and/or GA<30 weeks | Melbourne (AU) | 2001–2004 | 965 (239) | 27.6 (2.0) | 11% | 87% | 9% | 34% | 36% (Indomethacin administered) | °I–IV: 12% | 40.1 (1.7) | 1.5 T General Electric Signa System | Manual |
| Vasu | 19 (of 22)** | GA<32 weeks | London (UK) | 2007–2008 | 1260 (410) | 28.9 (2.8) | −0.13 (0.78) | N/A | N/A | 25% | 20% with pharmacological therapy | °III–IV: 5% | 40.2 (3.1) | 3 T Philips Achieva | Automatic |
N/A: Data not available in the published manuscript.
Brain volumetry was not available in all infants.
*Proportion with SDS for birth weight <-2/if marked as ‘SGA’, then proportion with birth weight <10th percentile.
†According to publication: Maunu et al. PIPARI Study Group. Ventricular dilatation in relation to outcome at 2 years of age in very preterm infants: a prospective Finnish cohort study. Dev Med Child Neurol. 2011 Jan;53(1):48–54.
‡According to personal communication with the author: MRI were performed at term (SD 5 days) in 93% of infants. The time between term age and imaging day was at most 29 days (in one infant).
§Only the percentage of ‘severe brain damage’; IVH °III and/or parenchymal haemorrhage and/or WMD was reported (12%).
¶From the original data reported by Tam et al, the infants meeting the inclusion criteria of this review were selected and analysed.
**Only the percentage of infants with hydrocortisone treatment was reported.26
††Patient characteristics were reported from the original population
bw, birth weight; GA, gestational age at birth; IVH, intraventricular haemorrhage; SGA, small for getational age; UBC, University of British Columbia; UCSF, University of California San Francisco; WMD, white matter disease.
Brain volume measurements (and weighted means) in preterm infants at term-equivalent age
| N | PMA at scan (weeks) | Total brain volume (mL) | Total cerebellar volume (mL) | Cortical grey matter volume (mL) | Unmyelinated white matter volume (mL) | |
| Blok | 36 | 41.4 (0.8) | 391 (34) | N/A |
|
|
| Ekblad | 209 | † | 397 (51.2) | 24.2 (5.1) | N/A | N/A |
| Hansen-Pupp | 51 | 40.1 (0.6) |
| 21.3 (2.7) | N/A |
|
| Hansen-Pupp | 49 | 40.1 (0.6) | 393 (50.9) |
| N/A | 190 (25) |
| Inder | 119 | 40.2 (0.3) | 406 (57) | N/A | 178 (41) | 202 (41) |
| Kamino | 44 | 37.7 (3.0) | N/A | 16.7 (5.3) | 107.6 (40.2) | 151 (20.1) |
| Moeskops | 85 | 41.1 (0.5) | N/A | N/A | 107 (13) | 171 (19) |
| Parikh | 122 | 38.5 (2.2) | 270 (41.5) | 16.1 (4.2) | 105 (19.1) | N/A |
| Steinhorn | 192 | ‡ |
| 21.4 (4.5) |
| N/A |
| Stiver | 105 | 41.9 (2.0) | N/A | 23.9 (5) | N/A | N/A |
| Tam | 68 | 39.5 (1.3) | N/A | 20.4 (5) | N/A | N/A |
| Thompson | 202 | 40.1 (1.7) | 395 (64) | N/A | 159 (41) | 212 (32) |
| Vasu | 19 | 40.2 (3.1) | 462 (12.8) | N/A | N/A | N/A |
| Aggregate data all studies |
|
|
|
| ||
| Aggregate data all studies |
|
|
|
| ||
| Aggregate data excluding reference |
|
|
| N/A | ||
*Not included in the meta-analysis.
†According to personal communication with the author: ‘MRI were performed at term (SD 5 days) in 93% of infants. The time between term age and imaging day was at most 29 days (in one infant).’ Out of 232 total MRI scans, 209 were successfully performed and analysed.
‡Between 38 and 42 weeks.
§Adjusted R2 for TBV 0.9850, for CV 0.9965, for CGM 0.8822, for UMWM 0.9906.
CGM, cortical grey matter; CV, cerebellar volume; N/A, not available; PMA, postmenstrual age; TBV, total brain volume; UMWM, unmyelinated white matter.
Figure 2Brain volumes by postmenstrual age (PMA) at MRI scan. CV, cerebellar volume; CGM, cortical grey matter volume; TBV, total brain volume; UMWM, unmyelinated white matter volume. Panels showing mean cerebral volumes according to mean PMA at MRI scan (with horizontal error bars indicating SD for PMA at MRI scan and vertical error bars indicating SD for volume). Sample size for each study is represented by the size of the symbol. Linear regression lines were calculated for each parameter taking sample size into account.
Figure 3Meta-analysis by simulation studies. CV, cerebellar volume; CGM, cortical grey matter volume; TBV, total brain volume; UMWM, unmyelinated white matter volume. Panels in the left column depict individual synthetic populations (according to simulations described in the Methods section), right column depicts summarising histograms and fitted Gaussian distributions. Resulting means, SDs and R2s are reported in table 2. Figure with permission and created by MW.